NASDAQ$ARQT
Arcutis Biotherapeutics Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Arcutis reported financial results for Q4 2020, highlighting progress in clinical trials and pipeline development.
Arcutis Biotherapeutics reported a net loss of $34.0 million for Q4 2020, with R&D expenses increasing to $27.4 million due to the initiation of multiple clinical trials. The company's cash, cash equivalents, restricted cash and marketable securities were $286.0 million as of December 31, 2020, which, combined with proceeds from a recent equity offering, is expected to fund operations into 2023.
- NDA submission for topical roflumilast cream in plaque psoriasis anticipated in the second half of 2021.
- Positive Phase 3 data on topical roflumilast cream in plaque psoriasis reported in February.
- Advancing topical roflumilast into Phase 3 programs for atopic dermatitis, seborrheic dermatitis, and scalp psoriasis during 2021.
- Strong financial position with over $470 million in cash, cash equivalents and marketable securities, providing cash runway into 2023.
Headline financials
Revenue & EPS history
Arcutis · Revenue · Quarterly
$105M
Forward guidance
Arcutis anticipates a transformational year in 2021, with plans to submit an NDA for topical roflumilast cream for plaque psoriasis and advance three additional programs into pivotal Phase 3 trials.
Tailwinds
- NDA submission for topical roflumilast cream as a potential treatment for plaque psoriasis anticipated in the second half of 2021.
- Pivotal Phase 3 trials in patients with atopic dermatitis (INTEGUMENT-1 and INTEGUMENT-2) initiated in January 2021 with topline data anticipated in the second half of 2022.
- Advancement of seborrheic dermatitis into Phase 3 development, anticipating initiation of a single pivotal Phase 3 study (STRATUM) in the second or third quarter of 2021, with topline data anticipated in the second or third quarter of 2022.
- Initiation of a Phase 2a study in vitiligo in the first quarter of 2021.
- Completion of enrollment of the ongoing Phase 1/2b study in chronic hand eczema, with topline data anticipated by mid-2021.
Headwinds
- Risks inherent in the clinical development process and regulatory approval process.
- Uncertainties related to the timing of regulatory filings.
- Potential challenges in defending intellectual property.
- The company's actual results may differ materially from forward-looking statements due to various risks and uncertainties.
- Pending discussions with regulators, the Company expects to initiate its Phase 3 program in scalp psoriasis in the second half of 2021, with topline data anticipated in the second half of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+1.8%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-0.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+27.2%
Q3 2025
Best reaction
-15.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.2% | -9.3% | -9.4% | |
| Q4 2025 | +5.7% | -12.6% | -21.4% | |
| Q3 2025 | +27.2% | +28.9% | +57.6% | |
| Q1 2025 | -4.6% | +0.5% | +0.3% | |
| Q4 2024 | +8.4% | +5.2% | +28.9% | |
| Q3 2024 | +11.8% | +16.6% | +33.3% | |
| Q2 2024 | -14.6% | -13.1% | +7.1% | |
| Q1 2024 | +15.6% | +15.1% | +16.9% | |
| Q4 2023 | +7.4% | +21.5% | +2.3% | |
| Q3 2023 | +5.4% | -0.9% | -10.4% | |
| Q2 2023 | -2.0% | -6.5% | -21.0% | |
| Q1 2023 | -15.6% | -29.3% | -29.8% | |
| Q4 2022 | +4.4% | -2.7% | -31.8% | |
| Q3 2022 | +0.6% | +3.1% | -8.4% | |
| Q2 2022 | +13.2% | +11.8% | +8.6% | |
| Q1 2022 | -11.8% | -14.1% | -3.5% | |
| Q4 2021 | +1.1% | +12.6% | +10.7% | |
| Q3 2021 | -7.5% | -6.9% | -35.6% | |
| Q2 2021 | +3.1% | +5.2% | +4.1% | |
| Q1 2021 | -3.4% | -1.8% | -23.1% | |
| Q4 2020 | -0.1% | +3.6% | -10.5% | |
| Q3 2020 | -3.8% | +8.9% | +37.1% | |
| Q2 2020 | +1.7% | +1.8% | -6.5% | |
| Q1 2020 | +0.0% | -4.6% | -4.6% | |
| Q4 2019 | +0.0% | -4.6% | -4.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro